VAXX (Vaxxinity) Research & Development: $35.90 Mil (TTM As of Dec. 2023)


What is Vaxxinity Research & Development?

Vaxxinity VAXX +39.29% Research & Development is $35.90 Mil as of Dec. 2023.

Research & Development is the aggregate amount of research and development expenses during the year. Vaxxinity's Research & Development for the three months ended in Dec. 2023 was $8.22 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 was $35.90 Mil.

Vaxxinity  (OTCPK:VAXX) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Vaxxinity Research & Development Related Terms

Vaxxinity Research & Development Historical Data

* Premium members only.

The historical data trend for Vaxxinity's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vaxxinity Research & Development Chart

Vaxxinity Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
10.66 20.57 71.38 47.63 35.90

Vaxxinity Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.02 11.42 8.35 7.91 8.22

Vaxxinity Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $35.90 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $35.90 Mil mean?
Vaxxinity (VAXX) has a Research & Development of $35.90 Mil as of Dec. 2023. Research and development expense is the total cost for research and development activities. View historical data on Vaxxinity and its competitors.
Is Vaxxinity's Research & Development too high?
Vaxxinity's current Research & Development is $35.90 Mil.
How does Vaxxinity's Research & Development compare to VBIVQ and AMPE?
Vaxxinity's Research & Development of $35.90 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Vaxxinity and its competitors. Vaxxinity's current Research & Development is $35.90 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vaxxinity stock overvalued right now?
Vaxxinity (VAXX) has a current Research & Development of $35.90 Mil. The current Research & Development is $35.90 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Vaxxinity (VAXX), the current Research & Development is $35.90 Mil as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vaxxinity Business Description

Address 505 Odyssey Way, Merritt Island, FL, USA, 32953
Vaxxinity Inc is a biotechnology company committed to democratizing healthcare across the globe. The company is pioneering a new class of synthetic, peptide-based active immunotherapy medicines aimed at disrupting the existing treatment paradigm for chronic disease, increasingly dominated by monoclonal antibodies, which suffer from prohibitive costs and cumbersome administration. The company's proprietary technology platform has enabled the innovation of novel pipeline candidates designed to bring the efficiency of vaccines to the treatment of chronic diseases, including Alzheimer's, Parkinson's, migraine, and hypercholesterolemia.